药品品牌转换:监管视角
本文从监管角度探讨仿制药替代原研药后出现的不良反应或疗效不佳报告问题。文章分析仿制药审批监管框架如何促成这一医学难题,并讨论药物基因组学在该情境中的潜在作用。
要点
- 仿制药需符合严格生物等效性标准,但首次及后续仿制药上市可能引发不安并增加不良反应或疗效失败报告。
- 仿制药替代与原研药转换后效应之间的因果关系难以评估。
- 监管框架可能促成品牌转换相关的医学难题,药物基因组学或可提供解释视角。
核心结论
- 仿制药替代原研药后可能出现不良反应或疗效失败报告增加,但因果关联难以确立。
- 仿制药审批监管框架可能促成了这一医学难题。
研究设计与样本
- 本文为监管视角的论述文章,主要探讨仿制药审批监管框架与品牌转换相关医学难题的关系。
主要发现
- 仿制药需满足严格生物等效性标准,但首次及后续仿制药上市可能引发不安并增加不良反应或疗效失败报告。
- 仿制药替代与原研药转换后效应之间的因果关系难以评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The replacement of expensive medications marketed by companies that bore the cost of development and testing, by low-cost "generics" once patent protection ends, is a common step in the life cycle of most drugs. Although generics are required to meet strict bioequivalence standards, the introduction of first-time and subsequent generics may lead to unease and increased reports of adverse effects or therapeutic failure. An established causal relationship between these effects and the switch from innovator to generic products can be challenging to assess. With the ongoing debate, this paper primarily explores how the regulatory framework governing generic drug approval may have contributed to this medical conundrum. In addition, we also offer a perspective on the potential role of pharmacogenetics within this setting.
引用
- Kee PS, Chin PKL, Tatley M, et al. Drug Brand Switching: A Regulatory Perspective. Drug Saf. 2026. PMID: 42821031. doi:10.1007/s40264-026-01712-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。